81 results
Page 3 of 5
8-K
ma60k4itpk 8xz
9 Nov 20
Two Confirmed Responses and Five out of Six Patients with Initial Tumor Reductions from Early Dose Cohorts of SURPASS Trial, Presented at SITC
5:11pm
8-K
988uh b5eo9niwt
15 Oct 20
Adaptimmune Provides Full Contents of its SITC Abstract for the Phase 1 SURPASS Trial
4:47pm
8-K
EX-99.1
nrrc1
15 Oct 20
Adaptimmune Provides Full Contents of its SITC Abstract for the Phase 1 SURPASS Trial
4:47pm
8-K
8em0ifc t05
29 May 20
Regulation FD Disclosure
7:42am
8-K
EX-99.1
4wut2j2ujttn
29 May 20
Regulation FD Disclosure
7:42am
8-K
EX-99.1
0bp43xzp9evl
14 May 20
Adaptimmune Reports Q1 Financial Results
7:37am
8-K
EX-99.1
jbi7t0w fm2
12 May 20
SPEAR T-cells Derived from Stem-Cells Kill Cancer Targets - Adaptimmune Presents Advances from its Allogeneic Platform at ASGCT Annual Meeting
10:54am
8-K
ulzqs1pmvzsi
12 May 20
SPEAR T-cells Derived from Stem-Cells Kill Cancer Targets - Adaptimmune Presents Advances from its Allogeneic Platform at ASGCT Annual Meeting
10:54am
8-K
EX-99.1
xc5tn5
29 Apr 20
Other Events
8:06am
424B5
lqbrtex189tspfe
22 Jan 20
Prospectus supplement for primary offering
5:31pm
424B5
2ek003a88rw1
21 Jan 20
Prospectus supplement for primary offering
5:21pm
8-K
EX-99.1
z6vgae1jn
30 Sep 19
Clear Benefit for Patients with Synovial Sarcoma Demonstrated in Updated Data from Ongoing
8:59am
8-K
69whrf
30 Sep 19
Clear Benefit for Patients with Synovial Sarcoma Demonstrated in Updated Data from Ongoing
8:59am
8-K
EX-99.1
ev0imgd b4
6 May 19
Significant Clinical Progress as Adaptimmune Announces Responses with ADP-A2M4 in Synovial Sarcoma and Antitumor Activity in Other Solid Tumors
7:08am
8-K
EX-99.1
rjd7uznal3
2 May 19
Other Events
7:10am